LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis (NCT06632457)
A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis
🩺 Plain-English Summary (8th-Grade Level)
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.
Who can join: Review the eligibility criteria below.
Location: The Institute for Liver Health II DBA Arizona Clinical Trials — Peoria, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (445 Sites)
Showing the first 25 of 445 sites.
- The Institute for Liver Health II DBA Arizona Clinical Trials — Peoria, Arizona
- Scottsdale Medical Specialists, Ltd — Scottsdale, Arizona
- Adobe Clinical Research, LLC — Tucson, Arizona
- Arizona Liver Health - Tucson — Tucson, Arizona
- Del Sol Research Management, LLC — Tucson, Arizona
- Hope Clinical Research — Canoga Park, California
- Velocity Clinical Research-Chula Vista — Chula Vista, California
- Southern California Research Center — Coronado, California
- ARK Clinical Research — Fountain Valley, California
- Velocity Clinical Research-Huntington Park — Huntington Park, California
- 310 Clinical Research — Inglewood, California
- Velocity Clinical Research, San Diego — La Mesa, California
- Om Research, LLC — Lancaster, California
- Catalina Research Institute, LLC — Montclair, California
- Clinnova Research Solutions — Orange, California
- Fomat Medical Research — Oxnard, California
- Cadena Care Institute, LLC — Poway, California
- Ficramed Research Institute — Poway, California
- Inland Empire Clinical Trials, LLC — Rialto, California
- Metro Clinical Trials — San Bernardino, California
- Acclaim Clinical Research — San Diego, California
- Future Innovative Treatments — Colorado Springs, Colorado
- South Denver Gastroenterology PC — Englewood, Colorado
- Connecticut Gastroenterology Clinical Research Foundation — Bristol, Connecticut
- Synergy Healthcare — Bradenton, Florida
📞 Contact the Study Coordinator
Phone: (800) 243-0127
Email: clintriage.rdg@boehringer-ingelheim.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Metabolic Dysfunction Associated Steatohepatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.